Gleamer SAS reported closing a series B round of $29.6 million to help expand its portfolio of artificial intelligence (AI) systems for radiologists and ramp international expansion. The exercise was led by Supernova Invest SAS who put up $11 million, joined by Heal Capital SAS with $5.5 million.
Compared to recent fundraising rounds in the med-tech space, Noah Medical Inc. was veritably deluged with cash in its series B. Softbank Vision Fund and Prosperity7 Ventures led the round, which rained down $150 million on the medical robotics company. Other participants included Hillhouse, Sequoia China, Shangbay Capital, Uphonest Capital, Sunmed Capital, Lyfe Capital, 1955 Capital, AME Cloud Ventures and undisclosed strategic investors.
Neuromod Devices Ltd. will use the €30 million (US$ 32.78 million) financing it recently raised to launch its tinnitus treatment device, Lenire, in the U.S. where there are an estimated 50 million Americans suffering from tinnitus, CEO, Ross O’Neill, told BioWorld. “To get this financing closed is very exciting as we go into the U.S. market which is the biggest hearing market in the world,” he added.
Ophthalmic startup Eluminex Biosciences Ltd. closed a $40 million series B round to progress its pipeline of ophthalmic assets and recombinant human collagen technology. Eluminex’s pipeline includes multi-targeted antibody molecules for vision-threatening retinal diseases and an oral small molecule for rare inherited pediatric retinal dystrophies, but its lead asset, EB-301, is a biosynthetic cornea derived from recombinant human type III collagen.
Volta Medical SAS reported raising $39 million in a series B round to roll out its VX1 software mapping system in Europe and the U.S. This artificial intelligence (AI) algorithm is compatible with most readily available multi-polar catheters and technology used in operating rooms and cath labs in the treatment of complex cardiac arrhythmia.
Suzhou Singular Medical Co. Ltd. has raised “hundreds of millions of RMB” in a series B+ round financing, which was jointly led by SDIC Chuanghe Fund Management Co. Ltd. and Qiming Venture Capital Management (Beijing) Co. Ltd.
Meccellis Biotech Group SAS reported closing an $8.25 million series B funding round to launch its biological implant technology on the US market. The exercise was supported by investment worth $5 million from Ocean Participations SAS alongside new funds from Volney Development SAS, Nouvelle-Aquitaine Co-Investissement SAS and the Poitou-Charentes business angel network Synergence Invest SAS.
While NASA gets the glory for exploration of the vast unknown of space, Bionaut Labs Ltd. hopes to reap similar fame by transforming travel through the brain with Bionauts, microrobots designed to deliver therapeutic payloads across the blood-brain barrier. To help achieve that mission, the company raised $43.2 million in a series B financing round led by Khosla Ventures.
Subtle Medical Inc. closed a series B financing to develop its artificial intelligence (AI) imaging enhancement solutions. Eastern Bell Venture Capital Management Co. Ltd. and Primavera Venture Partners lead this round of financing.
It was a good week for companies focused on minimally invasive brain surgery. Monteris Medical Corp. received $35 million in a series D equity financing and a $38 million debt facility to support market adoption and clinical research on its Neuroblate system, a laser ablation system that provides a minimally invasive option for brain surgery. Nico Corp. also raised additional funds, with a $12.5 million oversubscribed round for its devices, which do not require cutting through the brain but instead use the natural folds of the brain to reach abnormalities.